Tecentriq

• 

Atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer

By Sharon Kell|2019-06-03T08:08:23+00:003 Jun 2019|Drug treatments|

Results from this phase III trial of atezolizumab plus bevacizumab [...]

Read More

Comments Off on Atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer

• 

Safety and tolerability of atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer

By Sharon Kell|2018-11-05T11:24:08+00:005 Nov 2018|Drug treatments|

The combined safety results of two studies with the atezolizumab [...]

Read More

Comments Off on Safety and tolerability of atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer

• 

ESMO 2018: Cabozantinib in combination with atezolizumab in metastatic kidney cancer

By Sharon Kell|2018-11-05T10:38:57+00:005 Nov 2018|Drug treatments|

The following video interview from Practice Update discusses the promising results [...]

Read More

Comments Off on ESMO 2018: Cabozantinib in combination with atezolizumab in metastatic kidney cancer

• 

ESMO 2018: Cabozantinib/atezolizumab combination shows encouraging clinical activity for untreated advanced RCC

By Sharon Kell|2018-10-23T15:48:16+00:0023 Oct 2018|Drug treatments|

Results from the phase 1b COSMIC-021 study of cabozantinib in [...]

Read More

Comments Off on ESMO 2018: Cabozantinib/atezolizumab combination shows encouraging clinical activity for untreated advanced RCC

• 

Patient-reported outcomes for atezolizumab plus bevacizumab combination

By Sharon Kell|2018-06-07T14:45:15+00:007 Jun 2018|Drug treatments|

Patient-reported outcomes from the phase 3 IMmotion151 study, which assessed [...]

Read More

Comments Off on Patient-reported outcomes for atezolizumab plus bevacizumab combination

Atezolizumab plus bevacizumab combination is positive for untreated metastatic kidney cancer

By Sharon Kell|2018-02-06T15:34:35+00:006 Feb 2018|Drug treatments|

The combination of immunotherapy atezolizumab (Tecentriq) with targeted therapy bevacizumab [...]

Read More

Comments Off on Atezolizumab plus bevacizumab combination is positive for untreated metastatic kidney cancer

Positive interim results for atezolizumab plus bevacizumab combination in advanced RCC

By Sharon Kell|2017-12-12T14:01:05+00:0012 Dec 2017|Drug treatments|

Interim results from the phase III IMmotion151 study to assess [...]

Read More

Comments Off on Positive interim results for atezolizumab plus bevacizumab combination in advanced RCC

• 

Combination treatment with atezolizumab plus bevacizumab improves progression-free survival

By Sharon Kell|2017-09-12T16:26:45+00:0012 Sep 2017|Drug treatments|

Results from the IMmotion150 phase II clinical trial showed that [...]

Read More

Comments Off on Combination treatment with atezolizumab plus bevacizumab improves progression-free survival

Atezolizumab plus bevacizumab combination show promise for first-line kidney cancer treatment

By Sharon Kell|2017-02-24T15:46:23+00:0024 Feb 2017|Drug treatments|

Results from the IMmotion150 Phase 2 clinical trial, a global, [...]

Read More

Comments Off on Atezolizumab plus bevacizumab combination show promise for first-line kidney cancer treatment